Comparison of BCG and Mitomycin in treating urinary bladder tumor
Objective: Comparison of Mitomycin C and BCG in treating urinary bladder cancer to devise better agent with less complications and good outcomes.
Materials and Methods: The study was conducted at Mayo hospital, Lahore from January 2017 to January 2018. It included 60 patients suffering from urinary bladder tumor.
Results: The complications such as fever, hematuria and dysuria were more associated with BCG; however, it was found to be associated with less recurrence rate as compared to MMC.
Conclusion: BCG is more recommended to be used for treating urinary bladder cancer as compared to MMC.
Key Words: bladder cancer, BCG, MMC,
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.